BioSpace News Archive

Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST.

Oyster Point Pharma, Inc. today announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 90,800 shares of common stock to seven new employees.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.

Antengene Corporation Limited announced that management from Antengene will be participating in the 40th Annual J.P. Morgan Healthcare Conference in January 2022.

DreamTec Research Limited (DreamTec, http://www.dreamtec.hk) has its major breakthrough in developing a COVID-19 oral vaccine.

BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced it has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed “Zhangjiang Pharma Valley”, located in Zhangjiang Hi-Tech Park in Pudong, Shanghai.

Virpax® Pharmaceuticals, Inc. (“Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET.

Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical devices, announced the appointment of Guy Fish, M.D. to its Board of Directors.